Johnson & Johnson Commits $1 Billion to New Cell Therapy Facility in Pennsylvania
Johnson & Johnson executive vice president and CFO Joseph Wolk discusses the company’s performance and President Donald Trump’s healthcare agenda on The Claman Countdown.
Johnson & Johnson has announced a significant investment of over $1 billion to establish a next-generation manufacturing facility dedicated to advanced cell therapy technologies.
This new facility will be situated in Montgomery County, Pennsylvania. The company stated that this initiative will not only enhance its U.S. manufacturing capacity but also expand its pipeline of innovative medicines targeting cancer, immune-mediated, and neurological diseases.
Once fully operational, the facility is expected to create over 500 skilled biomanufacturing jobs and provide more than 4,000 construction jobs during its development phase.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” stated Johnson & Johnson CEO Joaquin Duato.
JOHNSON & JOHNSON INVESTING $2B IN US MANUFACTURING, CREATING NEW JOBS
Johnson & Johnson announced plans to invest $1 billion in a new gene therapy manufacturing facility in Pennsylvania. (Cristina Arias/Cover/Getty Images)
Duato further emphasized, “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”
This $1 billion investment is part of a broader strategy, with the company previously announcing plans to invest $55 billion in manufacturing, research and development, and technology in the U.S. through early 2029.
OBAMACARE ENROLLMENT FELL BY MORE THAN 1M ENROLLEES FOR 2026
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | 245.50 | +0.57 | +0.23% |
Johnson & Johnson highlighted that this facility will strengthen its presence in Pennsylvania, which contributes approximately $10 billion annually to the economy.
The company operates 10 facilities across Pennsylvania, covering over 2 million square feet, encompassing manufacturing, research, distribution, and office operations.
Johnson & Johnson’s investment is part of a previously announced $55 billion commitment. (Courtesy of Johnson & Johnson)
Pennsylvania Governor Josh Shapiro, a Democrat, remarked that this announcement underscores the state’s status as a “powerhouse for innovation and manufacturing in the life sciences.” He added that the Johnson & Johnson investment reflects that companies recognize Pennsylvania’s strategic advantages, skilled workforce, and operational efficiency.
“Pennsylvania leads in life sciences and advanced manufacturing because we consistently deliver what companies like Johnson & Johnson need to succeed: a skilled workforce, premier research institutions, and proven manufacturing strength,” stated Senator Dave McCormick, R-Pa. “This $1 billion-plus investment in a new Lower Gwynedd facility is a testament to that leadership and will produce life-changing treatments for patients, along with new and good jobs for our Commonwealth.”
GET FOX BUSINESS ON THE GO BY CLICKING HERE
“Pennsylvania is a leader in healthcare innovation with some of the very best healthcare workers. Proud to see this more than $1 billion investment into Montgomery County and our Commonwealth,” said Senator John Fetterman, D-Pa. “Bringing new jobs, advanced manufacturing, and life-saving medicine to and for our communities is always something to celebrate.”
Johnson & Johnson executive vice president and CFO Joseph Wolk discusses the company’s performance and President Donald Trump’s healthcare agenda on The Claman Countdown.
Johnson & Johnson has announced a significant investment of over $1 billion to establish a next-generation manufacturing facility dedicated to advanced cell therapy technologies.
This new facility will be situated in Montgomery County, Pennsylvania. The company stated that this initiative will not only enhance its U.S. manufacturing capacity but also expand its pipeline of innovative medicines targeting cancer, immune-mediated, and neurological diseases.
Once fully operational, the facility is expected to create over 500 skilled biomanufacturing jobs and provide more than 4,000 construction jobs during its development phase.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” stated Johnson & Johnson CEO Joaquin Duato.
JOHNSON & JOHNSON INVESTING $2B IN US MANUFACTURING, CREATING NEW JOBS
Johnson & Johnson announced plans to invest $1 billion in a new gene therapy manufacturing facility in Pennsylvania. (Cristina Arias/Cover/Getty Images)
Duato further emphasized, “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”
This $1 billion investment is part of a broader strategy, with the company previously announcing plans to invest $55 billion in manufacturing, research and development, and technology in the U.S. through early 2029.
OBAMACARE ENROLLMENT FELL BY MORE THAN 1M ENROLLEES FOR 2026
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | 245.50 | +0.57 | +0.23% |
Johnson & Johnson highlighted that this facility will strengthen its presence in Pennsylvania, which contributes approximately $10 billion annually to the economy.
The company operates 10 facilities across Pennsylvania, covering over 2 million square feet, encompassing manufacturing, research, distribution, and office operations.
Johnson & Johnson’s investment is part of a previously announced $55 billion commitment. (Courtesy of Johnson & Johnson)
Pennsylvania Governor Josh Shapiro, a Democrat, remarked that this announcement underscores the state’s status as a “powerhouse for innovation and manufacturing in the life sciences.” He added that the Johnson & Johnson investment reflects that companies recognize Pennsylvania’s strategic advantages, skilled workforce, and operational efficiency.
“Pennsylvania leads in life sciences and advanced manufacturing because we consistently deliver what companies like Johnson & Johnson need to succeed: a skilled workforce, premier research institutions, and proven manufacturing strength,” stated Senator Dave McCormick, R-Pa. “This $1 billion-plus investment in a new Lower Gwynedd facility is a testament to that leadership and will produce life-changing treatments for patients, along with new and good jobs for our Commonwealth.”
GET FOX BUSINESS ON THE GO BY CLICKING HERE
“Pennsylvania is a leader in healthcare innovation with some of the very best healthcare workers. Proud to see this more than $1 billion investment into Montgomery County and our Commonwealth,” said Senator John Fetterman, D-Pa. “Bringing new jobs, advanced manufacturing, and life-saving medicine to and for our communities is always something to celebrate.”
